Kaimi Biotech

Executive Summary

Kaimi Biotech is a private Chinese diagnostics company founded in 2020 and headquartered in Taizhou. The company specializes in developing and manufacturing innovative point-of-care diagnostic products using proprietary lateral flow assay technologies. Their key platforms include the Unow™ saliva/urine collection system and QiDix™ diagnostic products, which are designed to deliver high-performance testing for substance abuse and other applications. With a commercial-stage operation and a lean team of 10-50 employees, Kaimi focuses on novel material development and manufacturing processes to differentiate its offerings in the competitive POC testing market. The company is well-positioned to capitalize on the growing demand for rapid, non-invasive diagnostic solutions in China and potentially internationally. Despite limited public financial disclosures, Kaimi Biotech's emphasis on technological innovation and its established product platforms suggest a solid foundation for growth. The company's future success will depend on regulatory clearances, market adoption of its Unow™ and QiDix™ systems, and strategic partnerships. As a private entity, Kaimi may also attract investment to scale production and expand into new geographies. The competitive landscape in substance abuse testing remains intense, but Kaimi's proprietary technology and focus on point-of-care convenience provide a potential edge.

Upcoming Catalysts (preview)

• Q2 2026NMPA Approval for Expanded QiDix™ Test Menu65% success
• Q3 2026Strategic Distribution Partnership for Unow™ System50% success
• Q1 2027CE Marking for European Market Entry70% success